More Federal Tax Dollars Slip Away as Medtronic Buys Covidien
Insights - Medtronic (MDT) announced Sunday an agreement to buy Covidien (COV) in a $42.9 billion dollar cash and stock deal. The 29% premium is thought to … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
bluebird bio’s Treatment for a Rare Blood Disorder is Working
Insights - bluebird bio (BLUE) reported that two patients taking LentiGlobin had rapid and sustained responses to the gene therapy
Read now
Our Top Stories In Biotech This Week
Recap - Orexigen Therapeutics (OREX)Â got an unexpected surprise on Wednesday when the FDA extended its review of the New Drug Application for NB32, the company’s investigational drug … Continue Reading
Read now
How We Spotted This Winning Trade – Before It Happened
zFree - Conatus Pharmaceuticals (CNAT) closed Wednesday up 56% $6.05 on Tuesday $9.48 on Wednesday 56%. In a single session. With no news from Conatus this week and no groundbreaking events anticipated in … Continue Reading
Read now
Geron Trials Still on Hold While Collaborator Gets the Greenlight
Insights - Geron Corporation (GERN) announced on Thursday that the FDA has lifted a clinical hold on one trial of lead drug candidate, imetelstat, in myelofibrosis. Though … Continue Reading
Read now
Intercept Isn’t The Only Way to Play Rare Liver Diseases
Research - Intercept (ICPT) jumped to the top of many watchlists when a drug for liver diseases showed success in a P2 trial. Here's another, cheaper idea.
Read now
Orexigen Breaks Seven Dollars With PDUFA One Day Out
Research - Orexigen Therapeutics (OREX) broke above $7 in the Tuesday trading session, a day before the FDA issues a decision on the New Drug Application for NB32 (Contrave) as … Continue Reading
Premium